KR910000658A - 이미다졸릴- 알케노산 - Google Patents
이미다졸릴- 알케노산 Download PDFInfo
- Publication number
- KR910000658A KR910000658A KR1019900008739A KR900008739A KR910000658A KR 910000658 A KR910000658 A KR 910000658A KR 1019900008739 A KR1019900008739 A KR 1019900008739A KR 900008739 A KR900008739 A KR 900008739A KR 910000658 A KR910000658 A KR 910000658A
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- compound
- alkyl
- formula
- thienyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Polishing Bodies And Polishing Tools (AREA)
- External Artificial Organs (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (17)
- 일반식(Ⅰ)의 화합물 또는 약제학적으로 허용되는 염.
-
- R1은 비치환되거나, Cl, Br, F, I C1-C4알킬, 니트로, CO2R7, 테트라졸-5-일, C1-C4알콕시, 하이드록시, SC1-C4알킬, SO2NHR7, SO3H, CONR7R7, CN, SO2C1-C4알킬 및 CnF2n+1(여기에서 n은 1내지 3이다)중에서 선택된 하나 내지 3개의 치환체에 의해 치환된, 페닐, 비페닐, 나프틸, 또는 아다만틸 메틸이고: R2는 비치환되거나, C1-C4알킬, 니트로, Cl, Br, F, I, 하이드록실, C1-C4알콕시, NR7R7, CO2R7, CN 및 CONR7R7중에서 선택된 1 내지 3개의 치환체에 의해 치환된, C2-C10알킬, C3-C10알케닐, C3-C10알키닐, C3-C6사이클로알킬 또는 (CH2)0-8페닐이며: X는 단일결합, S 또는 O이고: R3은 수소, Cl, Br, F, I, CHO, 하이드록시메틸, COOR7, CONR7R7, NO2, 또 CnF2n+1(여기에서 n은 1내지 3이다)이며: R4및 R5는 독립적으로 수소, C1-C6알킬, 티에닐-Y-, 피라졸릴-Y-, 이미다졸릴-Y-, 티아졸리-Y-, 푸릴-Y-, 피롤릴-Y, 티아졸릴-Y-, 옥사졸릴-Y-, 이속사졸릴-Y-, 피리딜-Y- 또는 테트라졸릴-Y-이고, 단 R4및 R5는 모두 수소 및 C1-C4알킬 중에서 선택되어서는 안되며, 헤테로 사이클릭 환은 각각 비치환되거나, C1-C4알킬, C1-C4알콕시, Cl, Br, F, I, NR7R7, CO2R7, SO2NHR7, SO3H 또는 CONR7R|7에 의해 치환되어야 하고: Y는 단일결합, S, O 또는 직쇄 또는 측쇄이거나 페닐 또는 벤질로 임의 치환된 C1-C6알킬이며, 여기에서 아릴그룹은 각각 비치환되거나 할로, NO2, CF3, C1-C4알킬, C1-C4알콕시, CN, 또는 CO2R7에 의해 치환되고, R6는 -Z-COOR8또는 -Z-CONR7R7이며: Z는 단일결합: 비닐: -CH2-O-CH2-: C1-C4알킬, 페닐, 벤질, 티에닐메틸 또는 푸릴메틸이다)이고: R7는 각각 독립적으로 수소, C1-C4알킬, 또는 (CH2)m페닐(여기에서 m은 0내지 4이다)이며: R8은 수소, C1-C6알킬, 또는 2-디(C|1-C4알킬)아미노-2-옥소에틸이다.
- 제1항에 있어서, R1이 비치환되거나, 클로로, 플루오로, 트리플루오로메틸, 니트로, 메틸, 메톡시, 하이드록시, 설파이드, 시아노, 카복시, 카보-C1-C4알콕시, 카바모일 및 테트라졸-5-일 중에서 선택된 하나 내지 3개의 치환체에 의해 치환된 페닐이고: X가 단일결합이며; R2가 C2-C8알킬이고: R3가 수소, 클로로, 플루오로 또는 트리플루오로 메틸이며: R4가 수소, 또는 C1-C4알킬이고: R5가 각각 메틸 또는 메톡시에의해 임의로 치환된 티에틸메틸, 푸릴메틸, 이미다졸릴메틸 또는 피리딜메틸이며: R6가 COOH, COOC1-C2알킬, CONH2인 화합물.
- 제1항 또는 제2항에 있어서, E(트랜스)이성체인 화합물.
- 제1항에 있어서, (E)-3-[2-n-부틸-1-{(4-카복시페닐)메틸}-1H-이미다졸-5-일]-2-(2-티에닐)메틸-2-프로페논산 또는 이의 약제학적으로 허용되는 염.
- 제1항에 있어서, (E)-3-[2-n-부틸-1-{(4-카복시-3-클로로페닐)메틸}-1H-이미다졸-5-일]-2-(2-티에닐)메틸-2-프로페논산 또는 이의 약제학적으로 허용되는 염.
- 제1항에 있어서, (E)-3-[2-n-부틸-1-{(2-클로로페닐)메틸}-1H-이미다졸-5-일]-2-(2-티에닐)메틸-2-프로페논산, (E)-3-[2-n-부틸-1-{(4-카복시-2-클로로페닐)메틸}-1H-이미다졸-5-일]-2-(2-티에닐)메틸-2-프로페논산, (E)-3-[2-n-부틸-1-{(4-카복메톡시 페닐)메틸}-1H-이미다졸-5-일]-2-(2-티에닐)메틸-2-프로페논산, (E)-3-[2-n-헥실-1-{(4-카복시 페닐)메틸}-1H-이미다졸-5-일]-2-(2-티에닐)메틸-2-프로페논산, (E)-3-[2-n-프로필-1-{(4-카복시페닐)메틸}-1H-이미다졸-5-일]-2-(2-티에닐)메틸-2-프로페논산, (E)-3-[2-n-부틸-1-{(2-니트로페닐)메틸}-1H-이미다졸-5-일]-2-(2-티에닐)메틸-2-프로페논산, (E)-3-[2-n-부틸-1-{(2-클로로페닐)메틸}-1H-이미다졸-5-일]-2-(2-푸릴)메틸-2-프로페논산, (E)-3-[2-n-부틸-1-{(2-클로로페닐)메틸}-1H-이미다졸-5-일]-2-(4-이미다졸릴)메틸-2-프로페논산, (E)-3-[2-n-부틸-1-{(2-클로로페닐)메틸}-1H-이미다졸-5-일]-2-(3-티에닐)메틸-2-프로페논산, (E)-3-[2-n-부틸-1-{(2-클로로페닐)메틸}-1H-이미다졸-5-일]-2-(5-메틸-2-티에닐)메틸-2-프로페논산, (E)-3-[2-n-부틸-1-{(2-시아노페닐)메틸}-1H-이미다졸-5-일]-2-(2-티에닐)메틸-2-프로페논산, (E)-3-[2-n-부틸-1-{(4-메톡시-3-메틸페닐)메틸}-1H-이미다졸-5-일]-2-(2-티에닐)메틸-2-프로페논산, (E)-3-[2-n-부틸-1-{(2-클로로페닐)메틸}-1H-이미다졸-5-일]-2-(4-피리딜)메틸-2-프로페논산, (E)-3-[2-n-부틸-1-{(2-클로로페닐)메틸}-1H-이미다졸-5-일]-2-(5-메톡시-2-티에닐)메틸-2-프로페논산, (E)-3-[2-n-부틸-1-{(2,3-디클로로페닐)메틸}-1H-이미다졸-5-일]-2-(2-티에닐)메틸-2-프로페논산, 또는 (E)-3-[2-n-부틸-1-{(2-트리플루오로메틸페닐)메틸}-1H-이미다졸-5-일]-2-(2-티에닐)메틸-2-프로페논산: 또는 이의 약제학적으로 허용되는 염.
- 제1항 내지 제6항중 어느 한항에 따르는 화합물 및 이의 약제학적으로 허용되는 담체를 함유하는 약제학적 조성물.
- a)일반식(Ⅱ)의 화합물을 염기의 존재하에서 (C1-C4알콕시)2P(O)CH(R5)COOC1-C6알킬(여기에서 R5는 제1항에서 정의한 바와 같다)과 반응시키거나, b)일반식(Ⅲ)의 화합물을 일반식(Ⅳ)의 화합물과 반응시키거나, c)일반식(Ⅱ)의 화합물을 염기의 존재하에서 일반식(Ⅴ)의 화합물과 반응시키거나, d)일반식(Ⅳ)의 화합물을 염기와 반응시키거나, c)일반식(Ⅱ)의 화합물을 아세트산 무수물 중에서 염기의 존재하에 적절한 헤테로 사이클릭 아세트산과 반응시킨후: (i)상기와 같이 제조된 일반식(Ⅰ)의 에스테르 화합물을 환원시키고, 이어서, C1-C6알킬 할로아세테이트와 반응시켜 Z가 -CH2-O-CH2- 인 일반식(Ⅰ)의 화합물을 생성시키거나, (ⅱ)상기와 같이 제조된 일반식(Ⅰ)의 에스테르 화합물을 가수분해시키고, 이어서 아미노생성시약의 존재하에서 적절히 치환된 아미노산과 반응시켜 Z가 -C(O)NHCHR9-이고 R9이 수소, C1-C4알킬, 페닐, 벤질, 티에닐 메틸, 또는 푸릴메틸인 일반식(Ⅰ)의 화합물을 생성시키거나, (ⅲ)상기와 같이 제조된 일반식(Ⅰ)의 에스테르 화합물을 환원시키고, 이어서 C1-C6알킬과 반응시킨후 포스핀 리간드의 존재하에서 일산화탄소와 반응시켜 Z가 메틸렌그룹인 일반식(Ⅰ)의 화합물을 생성시키거나, (ⅳ)Z가 케틸렌그룹인 상기와 같이 제조된 일반식(Ⅰ)의 에스테르 화합물을 리튬 디알킬아미드와 반응시키고, 이어서 알킬화제와 반응시켜 Z가 C1-C4알킬, 벤질, 티에닐 메틸 또는 푸릴메틸에 의해 치환된 메틸렌그룹인 일반식(Ⅰ)의 화합물을 생성시킨후: 필요한 경우 (i)R1그룹이 C1-C4알콕시에 의해 치환된 일반식(Ⅰ)의 화합물을 탈보호시켜 R1그룹이 하이드록시에 의해 치환된 일반식(Ⅰ)의 화합물을 생성시키거나, (ⅱ)R1그룹이 CO2C1-C|4알킬에 의해 치환된 일반식(Ⅰ)의 화합물을 가수분해시켜 R1그룹이 카복시에 의해 치환된 일반식(Ⅰ)의 화합물을 생성시키거나, (ⅲ)R1그룹이 카복시에 의해 치환된 일반식(Ⅰ)의 화합물을 할로겐화제로 처리하고, 이어서 암모니아와 반응시켜 1급 아미드로 전환시키고, 옥살릴클로라이드/디케틸포름아미드로 탈수시키고, 아지드와 반응시켜, R1그룹이 테트라졸-5-일 그룹에 의해 치환된 일반식(Ⅰ)의 화합물을 생성시키거나, (ⅳ)R6가 -Z-COOC1-C6알킬인 일반식(Ⅰ)의 화합물을 가수분해시켜 R6가 -Z-COOH인 일반식(Ⅰ)의 화합물을 생성시키거나, (ⅴ)R6가 -Z-COOH인 일반식(Ⅰ)의 화합물을 할로겐화제로 처리하고, 이어서 적절히 치환된 아민과 반응시켜 R6가 -Z-CONR7R7이고 R7가 수소, C1-C4알킬 또는 (CH2)0-4페닐인 일반식(Ⅰ)의 화합물을 생성시킨후: 임의로 약제학적으로 허용되는 염을 형성시킴을 특징으로 하여, 제1항에서 정의한 일반식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염을 제조하는 방법.
-
- 상기식에서, R2,R3,R4,R5및 X는 제1항에서 정의한 바와 같고:R|1′는 제1항에서 정의한 R1이며, 단 R1′그룹상의 치환체는 테트라졸-5-일, OH, 또는 CO2H를 포함해서는 안되고: W는 Cl, Br, F, I, C1-C4알킬, 니트로, CO2C1-C|4알킬, C1-C4알콕시, SCC1-C4알킬, CN, SO2C1-C4알킬, SO2NHR|7, NHSO2C1-C4알킬 또는 CnF2n+1이며, 여기에서 n은 1 내지 3이고, p는 0 내지 3이며, R7은 수소, C1-C4알킬 또는 (CH2)0-4페닐이고: R11은 COCH3또는 SO2CH3이다.
- 안지오텐신Ⅱ수용체 길항작용이 한 인자인 질병을 치료하기 위한 약제를 제조하는데 있어서 제1항에서 정의한 일반식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염의 용도.
- 고혈압증을 치료하기 위한 약제를 제조하는데 있어서, 제1항에서 정의한 일반식(Ⅰ)의 화합물 또는이의 약제학적으로 허용되는 염의 용도.
- 울형성 심부전증을 치료하기 위한 약제를 제조하는데 있어서, 제1항에서 정의한 일반식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염의 용도.
- 신장병을 치료하기 위한 약제를 제조하는데 있어서 제1항에서 정의한 일반식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염의 용도.
- ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36607989A | 1989-06-14 | 1989-06-14 | |
US7/366079 | 1989-06-14 | ||
US366079 | 1989-06-14 | ||
US50641290A | 1990-04-06 | 1990-04-06 | |
US7/506412 | 1990-04-06 | ||
US506412 | 1990-04-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR910000658A true KR910000658A (ko) | 1991-01-29 |
KR0165837B1 KR0165837B1 (ko) | 1999-02-18 |
Family
ID=27003220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019900008739A KR0165837B1 (ko) | 1989-06-14 | 1990-06-14 | 이미다졸릴-알켄산 및 이의 제조방법 및 약제학적 조성물 |
Country Status (26)
Country | Link |
---|---|
EP (2) | EP0403159B1 (ko) |
JP (1) | JPH0768223B2 (ko) |
KR (1) | KR0165837B1 (ko) |
CN (2) | CN1027504C (ko) |
AT (2) | ATE250587T1 (ko) |
CA (1) | CA2018438C (ko) |
CY (1) | CY2232B1 (ko) |
DE (3) | DE10075018I2 (ko) |
DK (2) | DK0403159T3 (ko) |
ES (2) | ES2142789T3 (ko) |
FI (1) | FI102610B (ko) |
GR (1) | GR3033452T3 (ko) |
HK (2) | HK1025315A1 (ko) |
HU (1) | HU208537B (ko) |
IE (2) | IE902140A1 (ko) |
IL (1) | IL94698A (ko) |
LU (1) | LU90562I2 (ko) |
MA (1) | MA21896A1 (ko) |
NL (1) | NL300006I2 (ko) |
NO (1) | NO175977C (ko) |
NZ (1) | NZ233997A (ko) |
PH (1) | PH27592A (ko) |
PL (3) | PL165609B1 (ko) |
PT (1) | PT94377B (ko) |
SG (1) | SG52330A1 (ko) |
ZW (1) | ZW9490A1 (ko) |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5210079A (en) * | 1988-01-07 | 1993-05-11 | E. I. Du Pont De Nemours And Company | Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists |
US5185351A (en) * | 1989-06-14 | 1993-02-09 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists |
US5449682A (en) * | 1990-02-13 | 1995-09-12 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a substituted benzyl element |
DE122007000050I1 (de) * | 1990-02-19 | 2007-11-08 | Novartis Ag | Acylverbindungen |
WO1992000067A2 (en) * | 1990-06-22 | 1992-01-09 | E.I. Du Pont De Nemours And Company | Treatment of chronic renal failure with imidazole angiotensin-ii receptor antagonists |
NZ238688A (en) * | 1990-06-28 | 1992-05-26 | Smithkline Beecham Corp | Substituted histidines: pharmaceutical compositions, preparation and uses thereof |
NZ239161A (en) * | 1990-07-31 | 1994-01-26 | Smithkline Beecham Corp | Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments, |
GB9027197D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
US6025380A (en) * | 1990-12-14 | 2000-02-15 | Smithkline Beecham Plc | Medicament |
GB9027201D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
US5656650A (en) * | 1990-12-14 | 1997-08-12 | Smithkline Beecham Corp. | Angiotensin II receptor blocking compositions |
GB9027200D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
GB9027211D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
GB9027212D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
US6028091A (en) * | 1990-12-14 | 2000-02-22 | Smithkline Beecham Plc | Medicament |
GB9027208D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
US6034114A (en) * | 1990-12-14 | 2000-03-07 | Smithkline Beecham Plc | Medicament |
EP0565634B1 (en) * | 1990-12-14 | 1999-03-17 | Smithkline Beecham Corporation | Angiotensin ii receptor blocking compositions |
GB9027199D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
GB9027198D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
WO1992010189A1 (en) * | 1990-12-14 | 1992-06-25 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids |
GB9027210D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
GB9027209D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
EP0505098A1 (en) * | 1991-03-19 | 1992-09-23 | Merck & Co. Inc. | Imidazole derivatives bearing acidic functional groups as angiotensin II antagonists |
US5236928A (en) * | 1991-03-19 | 1993-08-17 | Merck & Co., Inc. | Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists |
US5187179A (en) * | 1991-03-22 | 1993-02-16 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a substituted imidazo [1,2-b][1,2,4]triazole |
US5128327A (en) * | 1991-03-25 | 1992-07-07 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle |
US5177074A (en) * | 1991-03-26 | 1993-01-05 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
US5252574A (en) * | 1991-04-26 | 1993-10-12 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a substituted thiophene or furan |
US5198438A (en) * | 1991-05-07 | 1993-03-30 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
GB9110532D0 (en) * | 1991-05-15 | 1991-07-03 | Smithkline Beecham Corp | Chemical compounds |
US5447949A (en) * | 1991-05-15 | 1995-09-05 | Smithkline Beecham Corporation | N-(heteroaryl) imidazolyl-alkenoic acids having angiotension II receptor antagonist activity |
GB9110636D0 (en) * | 1991-05-16 | 1991-07-03 | Glaxo Group Ltd | Chemical compounds |
US5175164A (en) * | 1991-06-05 | 1992-12-29 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted indole or dihydroindole |
DE4132632A1 (de) * | 1991-10-01 | 1993-04-08 | Bayer Ag | Substituierte imidazolyl-propensaeurederivate |
DE4132631A1 (de) * | 1991-10-01 | 1993-04-08 | Bayer Ag | Imidazolyl-propensaeurederivate |
DE4132633A1 (de) * | 1991-10-01 | 1993-04-08 | Bayer Ag | Cyclisch substituierte imidazolyl-propensaeurederivate |
GB9121463D0 (en) * | 1991-10-10 | 1991-11-27 | Smithkline Beecham Corp | Medicament |
US5389661A (en) * | 1991-12-05 | 1995-02-14 | Warner-Lambert Company | Imidazole and 1,2,4-triazole derivatives with angiotensin II antagonist properties |
US5322950A (en) * | 1991-12-05 | 1994-06-21 | Warner-Lambert Company | Imidazole with angiotensin II antagonist properties |
US5308853A (en) * | 1991-12-20 | 1994-05-03 | Warner-Lambert Company | Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties |
US5240953A (en) * | 1992-01-30 | 1993-08-31 | Ortho Pharmaceutical Corporation | Substituted triazoles as angiotensin ii inhibitors |
FR2687674B1 (fr) * | 1992-02-07 | 1995-05-19 | Roussel Uclaf | Nouveaux derives de la pyridone, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant. |
DE4206045A1 (de) * | 1992-02-27 | 1993-09-02 | Bayer Ag | Sulfonylbenzyl substituierte pyridone |
DE4206043A1 (de) * | 1992-02-27 | 1993-09-02 | Bayer Ag | Sulfonylbenzyl-substituierte imidazole |
DE4206042A1 (de) * | 1992-02-27 | 1993-09-02 | Bayer Ag | Sulfonylbenzyl-substituierte imidazopyridine |
DE4206041A1 (de) * | 1992-02-27 | 1993-09-02 | Bayer Ag | Sulfonylbenzyl-substituierte imidazolylpropensaeurederivate |
US5364869A (en) * | 1992-03-09 | 1994-11-15 | Abbott Laboratories | Heterocycle-substituted benzyaminopyridine angiotensin II receptor antagonists |
FR2689508B1 (fr) * | 1992-04-01 | 1994-06-17 | Fournier Ind & Sante | Derives de l'imidazole, leur procede de preparation et leur application en therapeutique. |
DE4210787A1 (de) * | 1992-04-01 | 1993-10-07 | Bayer Ag | Cycloalkyl- und Heterocyclyl substituierte Imidazolylpropensäurederivate |
DE4212796A1 (de) * | 1992-04-16 | 1993-10-21 | Bayer Ag | Propenoyl-imidazolderivate |
DE4215587A1 (de) * | 1992-05-12 | 1993-11-18 | Bayer Ag | Sulfonylbenzyl-substituierte Benzo- und Pyridopyridone |
DE4215588A1 (de) * | 1992-05-12 | 1993-11-18 | Bayer Ag | Biphenylmethyl-substituierte Pyridone |
DE4319041A1 (de) * | 1992-10-23 | 1994-04-28 | Bayer Ag | Trisubstituierte Biphenyle |
AU1884595A (en) * | 1994-04-29 | 1995-11-29 | Pfizer Inc. | Novel acyclic and cyclic amides as neurotransmitter release enhancers |
US20030004202A1 (en) | 1997-04-28 | 2003-01-02 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
EP0778833B1 (en) * | 1994-09-02 | 2002-05-15 | SmithKline Beecham Corporation | Endothelin receptor antagonists |
BR9611007A (pt) * | 1995-10-06 | 1999-07-13 | Novartis Ag | Antagonistas do receptor at1 para prevenir e tratar a deficiência renal pós-isquêmica e para a proteção de rins isquêmicos |
JP2000502104A (ja) * | 1995-12-21 | 2000-02-22 | スミスクライン・ビーチャム・コーポレイション | エンドセリン受容体アンタゴニスト |
DE69718146T2 (de) | 1996-02-29 | 2003-10-02 | Novartis Ag | At1 rezeptor antagonist zur anregung von apoptosis |
AR011126A1 (es) * | 1997-02-14 | 2000-08-02 | Smithkline Beecham Corp | Procedimiento para preparar eprosartano y compuestos intermediarios. |
CN1314881A (zh) | 1998-07-18 | 2001-09-26 | 拜尔公司 | 亚氨酰胺衍生物 |
CZ293257B6 (cs) | 1998-12-23 | 2004-03-17 | Novartis Ag | Farmaceutický přípravek obsahující antagonistu receptoru AT1 pro léčení nemocí spojených s nárůstem receptorů AT1 v subepiteliální vrstvě |
US6465502B1 (en) | 1998-12-23 | 2002-10-15 | Novartis Ag | Additional therapeutic use |
CN101011390A (zh) | 1999-01-26 | 2007-08-08 | 诺瓦提斯公司 | 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用 |
SE9903028D0 (sv) | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
AR033390A1 (es) | 2000-08-22 | 2003-12-17 | Novartis Ag | Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes |
US8168616B1 (en) | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
ATE383155T1 (de) * | 2003-07-31 | 2008-01-15 | Nicox Sa | Nitrooxyderivate von losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan als angiotensin-ii-rezeptor-blocker zur behandlung von herz-kreislauf-erkrankungen |
GB0327839D0 (en) | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
GB0402262D0 (en) | 2004-02-02 | 2004-03-10 | Novartis Ag | Process for the manufacture of organic compounds |
KR20070006774A (ko) | 2004-03-17 | 2007-01-11 | 노파르티스 아게 | 치료에서 레닌 억제제의 용도 |
CA2580862A1 (en) | 2004-10-08 | 2006-04-20 | Novartis Ag | Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure |
RU2007115900A (ru) | 2004-10-27 | 2008-11-10 | Дайити Санкио Компани, Лимитед (Jp) | Производные бензола, имеющие 2 или более заместителей |
CN101668525A (zh) | 2007-03-01 | 2010-03-10 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶抑制剂的新用途 |
EP2142514B1 (en) | 2007-04-18 | 2014-12-24 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
ES2393885T7 (es) | 2007-06-04 | 2014-01-30 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
JP2011500783A (ja) * | 2007-10-22 | 2011-01-06 | オーキッド リサーチ ラボラトリーズ リミテッド | ヒストンデアセチラーゼ阻害剤 |
ES2522968T3 (es) | 2008-06-04 | 2014-11-19 | Synergy Pharmaceuticals Inc. | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
AR072477A1 (es) * | 2008-07-11 | 2010-09-01 | Solvay Pharm Bv | Formulacion farmaceutica de eprosartan. uso. |
AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
WO2011004384A2 (en) | 2009-06-05 | 2011-01-13 | Glochem Industries Limited | Process for the preparation of eprosartan |
SG178953A1 (en) | 2009-09-11 | 2012-04-27 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
AP2014007766A0 (en) | 2011-12-15 | 2014-07-31 | Takeda Pharmaceuticals Usa Inc | Combination os azilsartan and chlorthlidone for treating hypertension black patients |
CN102584628B (zh) * | 2011-12-30 | 2015-04-22 | 浙江外国语学院 | 一种n-羧甲基戊脒的合成方法 |
JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
US10011637B2 (en) | 2013-06-05 | 2018-07-03 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5671073A (en) * | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | Imidazole derivative |
JPS5671074A (en) * | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative |
JPS58157768A (ja) * | 1982-03-16 | 1983-09-19 | Takeda Chem Ind Ltd | 4−クロロ−2−フエニルイミダゾ−ル−5−酢酸誘導体 |
US4668794A (en) * | 1985-05-22 | 1987-05-26 | Sandoz Pharm. Corp. | Intermediate imidazole acrolein analogs |
CA1334092C (en) * | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
US4835154A (en) * | 1987-06-01 | 1989-05-30 | Smithkline Beckman Corporation | 1-aralykyl-5-piperazinylmethyl-2-mercaptoimidazoles and 2-alkylthioimidazoles and their use as dopamine-βhydroxylase inhibitors |
US4798843A (en) * | 1987-07-09 | 1989-01-17 | Smithkline Beckman Corporation | 2-mercaproimidazole dopamine-β-hydroxylase inhibitors |
CA1338238C (en) * | 1988-01-07 | 1996-04-09 | David John Carini | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids |
-
1990
- 1990-06-07 AT AT99115614T patent/ATE250587T1/de not_active IP Right Cessation
- 1990-06-07 EP EP90306204A patent/EP0403159B1/en not_active Expired - Lifetime
- 1990-06-07 DE DE2000175018 patent/DE10075018I2/de active Active
- 1990-06-07 CA CA002018438A patent/CA2018438C/en not_active Expired - Lifetime
- 1990-06-07 ES ES90306204T patent/ES2142789T3/es not_active Expired - Lifetime
- 1990-06-07 DK DK90306204T patent/DK0403159T3/da active
- 1990-06-07 EP EP99115614A patent/EP0955294B1/en not_active Expired - Lifetime
- 1990-06-07 ES ES99115614T patent/ES2207091T3/es not_active Expired - Lifetime
- 1990-06-07 SG SG1996002914A patent/SG52330A1/en unknown
- 1990-06-07 AT AT90306204T patent/ATE190051T1/de active
- 1990-06-07 DK DK99115614T patent/DK0955294T3/da active
- 1990-06-07 DE DE69033469T patent/DE69033469T2/de not_active Expired - Lifetime
- 1990-06-07 DE DE69034103T patent/DE69034103T2/de not_active Expired - Lifetime
- 1990-06-08 ZW ZW94/90A patent/ZW9490A1/xx unknown
- 1990-06-08 NZ NZ233997A patent/NZ233997A/en unknown
- 1990-06-11 IL IL9469890A patent/IL94698A/en unknown
- 1990-06-11 PH PH40649A patent/PH27592A/en unknown
- 1990-06-12 PT PT94377A patent/PT94377B/pt not_active IP Right Cessation
- 1990-06-12 PL PL90285591A patent/PL165609B1/pl unknown
- 1990-06-12 PL PL90301864A patent/PL166722B1/pl unknown
- 1990-06-12 PL PL90301863A patent/PL166669B1/pl unknown
- 1990-06-13 MA MA22145A patent/MA21896A1/fr unknown
- 1990-06-13 FI FI902970A patent/FI102610B/fi active IP Right Grant
- 1990-06-13 IE IE214090A patent/IE902140A1/en not_active IP Right Cessation
- 1990-06-13 NO NO902632A patent/NO175977C/no not_active IP Right Cessation
- 1990-06-13 IE IE20000297A patent/IE20000297A1/en unknown
- 1990-06-14 JP JP2156627A patent/JPH0768223B2/ja not_active Expired - Lifetime
- 1990-06-14 HU HU903847A patent/HU208537B/hu unknown
- 1990-06-14 CN CN90104438A patent/CN1027504C/zh not_active Expired - Lifetime
- 1990-06-14 KR KR1019900008739A patent/KR0165837B1/ko not_active IP Right Cessation
-
1993
- 1993-03-16 CN CN93103111A patent/CN1048159C/zh not_active Expired - Lifetime
-
1998
- 1998-12-16 HK HK00102605A patent/HK1025315A1/xx not_active IP Right Cessation
- 1998-12-16 HK HK98113609A patent/HK1012384A1/xx not_active IP Right Cessation
-
2000
- 2000-04-05 LU LU90562C patent/LU90562I2/xx unknown
- 2000-05-16 NL NL300006C patent/NL300006I2/nl unknown
- 2000-05-19 GR GR20000401140T patent/GR3033452T3/el not_active IP Right Cessation
-
2001
- 2001-09-03 CY CY0100023A patent/CY2232B1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR910000658A (ko) | 이미다졸릴- 알케노산 | |
KR910000659A (ko) | 이미다졸릴-알케노산 | |
KR910007918A (ko) | 치환된5-[(테트라졸릴)알케닐]이미다졸 | |
KR900701782A (ko) | 퀴누클리딘 치료제 | |
KR920014805A (ko) | 퀴나졸리논 화합물, 그의 제약학적 조성물 및 그의 제조방법 | |
KR960703858A (ko) | 물질 p 길항제로서의 퍼히드로이소인돌 유도체(perhydroisoindole derivatives as substance p antagonists) | |
BR9104181A (pt) | Composto | |
KR910009659A (ko) | 신규한 이소인돌론 유도체, 그들의 제조 방법 및 그들을 함유한 제약학적 조성물 | |
KR910011798A (ko) | 치환된 5-(알킬)카복스아미드 이미다졸 | |
KR880006241A (ko) | 9-사이클로펜틸- 치환된 아데닌 유도체 | |
KR900011760A (ko) | 신규한 벤조 피란 유도체, 그 제조 및 상기 유도체를 함유하는 제약학적 조성물 | |
KR880009936A (ko) | 피리딘-2,4-및-2,5-디카복실산 아미드, 그의 제조방법 및 용도 | |
KR910009669A (ko) | 치환된 n-(이미다졸릴)알킬 알라닌 유도체 | |
KR930701411A (ko) | 치환된 히스티딘 | |
RU2006130002A (ru) | ПРОИЗВОДНЫЕ ТРИАЗОЛА В КАЧЕСТВЕ АНТАГОНИСТОВ А2b | |
ZA200402806B (en) | Alkyl ether derivatives or their salts | |
ES431307A1 (es) | Procedimiento para la preparacion de nuevos derivados de quinoleina. | |
KR900011728A (ko) | 5-리폭시게나제 억제제로서의 치환된 인돌, 벤조푸란 및 벤조티오펜 유도체 | |
JPS63295540A (ja) | Z−2−アシルアミノ−3−モノ置換プロペノエート | |
US4619944A (en) | Antihypertensive compounds | |
ATE37872T1 (de) | Phenylinden-derivate, ihre salze, und verfahren zu ihrer herstellung. | |
KR850001170A (ko) | 치환된 비닐 유도체의 제조방법 | |
KR920007999A (ko) | 4-또는 5-치환된 피리딘-2-카복실산. 이들의 제조방법 및 약제로서 이들의 용도 | |
WO1990004393A1 (en) | Prodrugs of antiinflammatory 3-acyl-2-oxindole-1-carboxamides | |
KR880005138A (ko) | 신규 화합물들 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
A101 | Application to extend term of patent right by permit | ||
A101 | Application to extend term of patent right by permit | ||
FPAY | Annual fee payment |
Payment date: 20120830 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20130329 Year of fee payment: 16 |
|
EXPY | Expiration of term |